JPWO2023194501A5 - - Google Patents
Info
- Publication number
- JPWO2023194501A5 JPWO2023194501A5 JP2024559214A JP2024559214A JPWO2023194501A5 JP WO2023194501 A5 JPWO2023194501 A5 JP WO2023194501A5 JP 2024559214 A JP2024559214 A JP 2024559214A JP 2024559214 A JP2024559214 A JP 2024559214A JP WO2023194501 A5 JPWO2023194501 A5 JP WO2023194501A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- sequence number
- cdr1
- cdr2
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263327757P | 2022-04-05 | 2022-04-05 | |
| US63/327,757 | 2022-04-05 | ||
| US202263478068P | 2022-12-30 | 2022-12-30 | |
| US63/478,068 | 2022-12-30 | ||
| PCT/EP2023/059054 WO2023194501A1 (en) | 2022-04-05 | 2023-04-05 | Treatment of myeloid disorders and acute leukemias targeting novel tumor specific antigens |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025511758A JP2025511758A (ja) | 2025-04-16 |
| JP2025511758A5 JP2025511758A5 (https=) | 2026-04-13 |
| JPWO2023194501A5 true JPWO2023194501A5 (https=) | 2026-04-13 |
Family
ID=86226509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559214A Pending JP2025511758A (ja) | 2022-04-05 | 2023-04-05 | 新規腫瘍特異的抗原を標的とする骨髄性障害および急性白血病の処置 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4504784A1 (https=) |
| JP (1) | JP2025511758A (https=) |
| KR (1) | KR20250042204A (https=) |
| CN (1) | CN119317643A (https=) |
| AU (1) | AU2023250214A1 (https=) |
| CA (1) | CA3255414A1 (https=) |
| IL (1) | IL316118A (https=) |
| MX (1) | MX2024012390A (https=) |
| WO (1) | WO2023194501A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025113635A1 (zh) * | 2023-12-01 | 2025-06-05 | 上海祥耀生物科技有限责任公司 | 抗cd84抗体及其用途 |
| CN118440198B (zh) * | 2024-04-03 | 2024-11-15 | 武汉爱博泰克生物科技有限公司 | 抗人cd69蛋白的兔单克隆抗体及其应用 |
| CN120678778B (zh) * | 2025-05-12 | 2026-01-27 | 山东康盛医疗器械股份有限公司 | 药物组合物在弥漫大b细胞淋巴瘤治疗中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| MX379256B (es) | 2013-03-15 | 2025-03-10 | Regeneron Pharma | Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos. |
| ES3063961T3 (en) * | 2014-02-14 | 2026-04-21 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| WO2018002902A1 (en) | 2016-07-01 | 2018-01-04 | Glaxosmithkline Intellectual Property (No.2) Limited | Antibody-drug conjugates and therapeutic methods using the same |
| EP3793591A1 (en) * | 2018-05-17 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
| US12534532B2 (en) * | 2018-10-26 | 2026-01-27 | Crage Medical Co., Limited | CLL1-targeting antibody and application thereof |
| US20240180963A1 (en) * | 2021-04-05 | 2024-06-06 | Altheia Science S.R.L. | Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigens |
-
2023
- 2023-04-05 CA CA3255414A patent/CA3255414A1/en active Pending
- 2023-04-05 JP JP2024559214A patent/JP2025511758A/ja active Pending
- 2023-04-05 WO PCT/EP2023/059054 patent/WO2023194501A1/en not_active Ceased
- 2023-04-05 IL IL316118A patent/IL316118A/en unknown
- 2023-04-05 CN CN202380044838.8A patent/CN119317643A/zh active Pending
- 2023-04-05 KR KR1020247036862A patent/KR20250042204A/ko active Pending
- 2023-04-05 AU AU2023250214A patent/AU2023250214A1/en active Pending
- 2023-04-05 EP EP23719650.6A patent/EP4504784A1/en active Pending
-
2024
- 2024-10-04 MX MX2024012390A patent/MX2024012390A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7551693B2 (ja) | ＮＫｐ４６結合タンパク質の可変領域 | |
| US11524991B2 (en) | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof | |
| CN113840634A (zh) | 可活化蛋白质构建体及其用途 | |
| CN113438961A (zh) | 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白 | |
| CN111148761A (zh) | 多特异性抗体及其制备和使用方法 | |
| TWI874613B (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| CN116041530A (zh) | 多特异性抗体及其制备和使用方法 | |
| CN113150156B (zh) | 抗tigit抗体及其用途 | |
| JP2022508529A (ja) | 二重標的抗原結合分子 | |
| CA3096791C (en) | Cell engaging binding molecules | |
| JP7592712B2 (ja) | ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法 | |
| EP4377358A1 (en) | Novel anti-sirpa antibodies | |
| CN114945596A (zh) | 用于调节免疫细胞衔接效应的手段和方法 | |
| JP2026062861A (ja) | 治療的タンパク質の薬物送達システム構成要素への吸着を防ぐ方法および組成物 | |
| CN110964114A (zh) | 一种双靶点抗原结合分子 | |
| WO2022002006A1 (zh) | Fab-HCAb结构的结合蛋白 | |
| JPWO2023194501A5 (https=) | ||
| TW202525853A (zh) | 抗ｃｄ２０ｘ抗ｃｄ２８組合療法 | |
| JP7854121B2 (ja) | 微小ガイダンス及びナビゲーションコントロール（ｍｉｎｉＧＮＣ）抗体様タンパク質、その製造方法及び使用方法 | |
| JPWO2022214499A5 (https=) | ||
| JP7851303B2 (ja) | ヒトｃｄ３イプシロンに結合する新規なヒト抗体 | |
| HK40073541A (en) | Miniature guidance and navigation control (minignc) antibody-like proteins and methods of making and using thereof | |
| HK40082471A (en) | Binding protein having h2l2 and hcab structures | |
| WO2022063314A1 (zh) | 靶向PD-1或PD-L1和TGF-β的双功能蛋白及其医药用途 | |
| HK40018991A (en) | Multi-specific antibodies and methods of making and using thereof |